Clinical Trial Update: Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) [Phase 2]

View source ↗

Summary

Phase 2 MATCH subprotocol update evaluating GSK2636771 for cancers with PTEN genetic changes; results were posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Tumor

Drugs mentioned

• GSK2636771

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-31